Active substanceSodium HeparinSodium Heparin
Similar drugsTo uncover
  • Heparin
    solution in / in PC 
    ALVILS, LTD.     Russia
  • Heparin
    solution in / in PC 
    BINERGIYA, CJSC     Russia
  • Heparin
    solution in / in PC 
    ELFA NPC, CJSC     Russia
  • Heparin
    gel externally 
  • Heparin
    gel externally 
  • Heparin
    solution in / in PC 
  • Heparin
    solution in / in PC 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Heparin
    solution in / in PC 
  • Heparin
    solution in / in PC 
  • Heparin
    solution for injections 
    SYNTHESIS, OJSC     Russia
  • Heparin
    solution in / in PC 
  • Heparin
    gel externally 
    GREEN DUBRAVA, CJSC     Russia
  • Heparin
    gel externally 
  • Heparin 1000
    gel externally 
    ATOLL, LLC     Russia
  • Heparin J
    solution in / in PC 
    JODAS EKSPOIM, LLC     Russia
  • Sodium Heparin
    solution in / in PC 
    ELLARA, LTD.     Russia
  • Sodium Heparin
    solution in / in PC 
    INDUKERN-RUS, OOO     Russia
  • Sodium Heparin
    solution in / in PC 
  • Heparin-Akrihin 1000
    gel externally 
    AKRIKHIN HFK, JSC     Russia
  • Heparin-sodium Brown
    solution in / in PC 
  • Heparin-Ferein®
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Lavenum®
    gel externally 
    POLLO, LLC     Russia
  • Lyoton® 1000
    gel externally 
  • Trombles®
    gel externally 
    NIZHFARM, JSC     Russia
  • Thrombogel 1000
    gel externally 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Dosage form: & nbspinjection
    Composition:

    Active substance: Sodium Heparin-5000 IU

    Excipients: gasoline alcohol (alcohol gasoline) - 9.0 mg, sodium chloride - 3.4 mg, water for injection - up to 1 ml.

    Description:Colorless or light yellow transparent liquid.
    Pharmacotherapeutic group:Anticoagulant straight
    ATX: & nbsp

    B.01.A.B.01   Heparin

    Pharmacodynamics:

    Anticoagulant direct action, refers to the group of medium-molecular heparins, slows the formation of fibrin. Anticoagulant effect is detected in vitro and in vivo, occurs immediately after intravenous application.

    The mechanism of action of heparin is based primarily on its binding to antithrombin III-inhibitor of activated blood coagulation factors: thrombin, IXa, Xa, XIa, XIIa (especially important is the ability to inhibit thrombin and activated factor X).

    Heparin disrupts the prothrombin transition in thrombin, depresses thrombin and stops the formation of fibrin from fibrinogen, and also to some extent reduces the aggregation of platelets.

    Increases renal blood flow; increases the resistance of blood vessels of the brain, reduces the activity of brain hyaluronidase, activates lipoprotein lipase and has lipid-lowering effect.

    Reduces the activity of the surfactant in the lungs, suppresses the excessive synthesis of aldosterone in the adrenal cortex, binds adrenaline, modulates the ovarian response to hormonal stimuli, and increases the activity of parathyroid hormone. As a result of interaction with enzymes, it can increase the activity of brain tyrosine hydroxylase, pepsinogen, DNA polymerase and reduce the activity of myosin ATPase, pyruvate kinase, RNA polymerase, pepsin.

    In patients with ischemic heart disease (in combination with acetylsalicylic acid) reduces the risk of developing acute coronary thrombosis, myocardial infarction and sudden death. Reduces the frequency of recurrent myocardial infarction and mortality of patients with myocardial infarction.

    In high doses it is effective for pulmonary embolism and venous thrombosis, in small doses for prophylaxis of venous thromboembolism, incl. after surgical operations.

    With intravenous administration, blood clotting slows down almost immediately, with intramuscular injection - after 15-30 minutes, with subcutaneous - after 20-60 minutes, after inhalation, the maximum effect-in a day; the duration of the anticoagulant effect is 4-5, 6, 8 hours and 1-2 weeks, respectively, and the therapeutic effect - prevention of thrombus formation - lasts much longer.

    Deficiency of antithrombin III in plasma or in the place of thrombosis can reduce the antithrombotic effect of heparin.

    Pharmacokinetics:

    After subcutaneous administration of TСmах - 4-5 hours. The connection with plasma proteins is up to 95%, the volume of distribution is very small - 0.06 l / kg (does not leave the vascular bed due to strong binding to plasma proteins). It does not penetrate the placenta and into breast milk. Intensively captured by endothelial cells and cells of the mononuclear-macrophage system (cells of the reticulo-endothelial system), it is concentrated in the liver and spleen. With the inhalation route of administration, it is absorbed by alveolar macrophages,endothelium of capillaries, large blood and lymphatic vessels: these cells are the main place of heparin deposition, from which it is gradually released, maintaining the necessary concentration in the plasma.

    It is metabolized in the liver with the participation of N-desulfamidase and platelet heparinase, which is included in the metabolism of heparin at later stages. Participation in the metabolism of platelet factor IV (anti-heparin factor), as well as the binding of heparin to the macrophage system, explains the rapid biological inactivation and short-term action. Desulfated molecules under the influence of kidney endoglycosidase are converted into low-molecular fragments. The half-life of the drug is -1-6 h (average -1.5 h); increases with obesity, hepatic and / or renal insufficiency; decreases with thromboembolism of the pulmonary artery, infections, malignant tumors. It is excreted by the kidneys, mainly in the form of inactive metabolites, and only with the introduction of high doses is it possible to excrete (up to 50%) unchanged. It is not excreted by hemodialysis.

    Indications:Prophylaxis and therapy: deep vein thrombosis, pulmonary embolism (incl.with peripheral veins), coronary artery thrombosis, thrombophlebitis, unstable angina, acute myocardial infarction, atrial fibrillation (including accompanied by embolization), DIC syndrome, prevention and therapy of microthrombosis and microcirculation disorders, renal vein thrombosis, hemolytic syndrome, mitral heart disease (prevention of thrombosis), bacterial endocarditis, glomerulonephritis, lupus nephritis. Prevention of blood coagulation during operations using extracorporeal circulation methods, hemodialysis, hemosorption, peritoneal dialysis, cythereferis, forced diuresis, washing of venous catheters.
    Contraindications:Hypersensitivity to heparin, diseases accompanied by increased hemorrhage (hemophilia, thrombocytopenia, vasculitis, etc.), bleeding, aneurysm of cerebral vessels, exfoliating aortic aneurysm, hemorrhagic stroke, antiphospholipid syndrome, trauma (especially cryo-cerebral), uncontrolled arterial hypertension, erosive - ulcerative lesions of the gastrointestinal tract; cirrhosis of the liver,accompanied by varicose veins of the esophagus; menstrual period, threatening miscarriage, childbirth (including recent ones), recent surgical interventions on the eyes, brain, prostate, liver and biliary tract, condition after spinal cord puncture, pregnancy, lactation.
    Carefully:Persons suffering from polyvalent allergy (including bronchial asthma); arterial hypertension, dental manipulations, diabetes mellitus, endocarditis, pericarditis, IUD, active tuberculosis, radiation therapy, hepatic insufficiency, chronic renal failure, elderly age (over 60 years, especially women).
    Dosing and Administration:

    Heparin is prescribed in the form of continuous intravenous infusion or in the form of regular intravenous injections, as well as subcutaneously (in the abdomen).

    For prophylactic purposes, subcutaneously, 5000 IU / day, at intervals of 8-12 hours. The usual place for injections is the anterolateral wall of the abdomen (in exceptional cases, it is inserted into the upper region of the shoulder or thigh), using a thin The needle, which should be inserted deep, perpendicular, into the fold of the skin,held between the thumb and index finger until the end of the solution. Each time, alternate injection sites (to avoid the formation of a hematoma). The first injection should be performed 1-2 hours before the operation; In the postoperative period, administer within 7-10 days, and if necessary - for a longer time.

    The initial dose of heparin administered for therapeutic purposes is usually 5000 IU and is administered intravenously, after which the treatment is continued using intravenous infusions. Supporting doses are determined depending on the method of application:

    - with continuous intravenous infusion, appoint 1000-2000 IU / h (24000-48000 IU / day), diluting heparin in a 0.9% solution of sodium chloride;

    - with periodic intravenous injections, 5000-10000 IU of heparin is administered every 4 hours.

    Adults with thromboses of mild to moderate severity, the drug is administered intravenously at a dose of 40000-50000 IU / day, divided by 3-4 times; with severe thrombosis and embolism-intravenously at a dose of 80000 IU / day, divided into 4 times with an interval of 6 hours. For vital indications, intravenously injected 25000 ME (5 ml), then 20000 IU every 4 hours until a daily dose of 80000 - 120000 ME.When intravenous drip infusion to the daily volume of the infusion solution, it is necessary to add at least 40,000 IU of heparin. Doses of heparin for intravenous administration are selected so that the activated partial thromboplastin time (APTT) was 1.5-2.5 times greater than the control one. When subcutaneous administration of small doses (5000 IU 2-3 times a day) for the prevention of thrombus formation, regular monitoring of APTTV is not required, it increases slightly.

    Continuous intravenous infusion is the most effective way of using heparin, better than regular (periodic) injections, because provides more stable hypocoagulation and less often causes bleeding.

    When carrying out the extracorporeal circulation, administer a dose of 140-400 IU / kg or 1500-2000 IU per 500 ml of blood. In hemodialysis, 10,000 IU is administered intravenously first, then in the middle of the procedure, another 30,000-50000 ME. For the elderly, especially women, the dose should be reduced.

    For children, the drug is administered intravenously drip: at the age of 1-3 months - 800 IU / kg / day, 4-12 months - 700 IU / kg / day, over 6 years - 500 IU / kg / day under the control of APTTV.

    Side effects:

    Allergic reactions: hyperemia of the skin, drug fever, urticaria, rhinitis, f itching itching and sensation of heat in the soles, bronchospasm, collapse,anaphylactic shock.

    Dizziness, headaches, nausea, decreased appetite, vomiting, diarrhea.

    Thrombocytopenia (6% of patients). Reactions of the first type, as a rule, appear in a mild form and disappear after discontinuation of therapy; Thrombocytopenia has a severe course and can be fatal.

    Against the background of heparin-induced thrombocytopenia, skin necrosis, arterial thrombosis, accompanied by the development of gangrene, myocardial infarction, stroke. With the development of severe thrombocytopenia (a decrease in the number of platelets by 2 times from the initial number or below 100,000 / mm3), it is urgent to stop the use of heparin.

    Against the background of long-term use - osteoporosis, spontaneous bone fractures, calcification of soft tissues, hypoaldosteronism, transient alopecia, increased activity of "liver" transaminases.

    Local reactions: irritation, pain, hyperemia, hematoma and ulceration at the site of injection, bleeding (the risk can be minimized by careful assessment of contraindications, regular laboratory blood coagulation and accurate dosage).

    Typical bleeding from the gastrointestinal tract and urinary tract,bleeding at the injection site, in areas under pressure, from surgical wounds, as well as hemorrhage in other organs (adrenal glands, yellow body, retroperitoneal space).

    Overdose:

    Symptoms: signs of bleeding.

    Treatment: with small bleeding caused by an overdose of heparin, it is enough to stop using it. With extensive bleeding, excess heparin is neutralized with protamine sulfate (1 mg protamine sulphate per 100 IU of heparin). It must be borne in mind that heparin is rapidly excreted, and if Protamine sulfate appointed 30 minutes after the previous dose of heparin, only half the required dose should be administered; The maximum dose of protamine sulfate is 50 mg.

    Hemodialysis is ineffective.

    Interaction:

    The action of heparin is enhanced by certain antibiotics (reduce the formation of vitamin K by intestinal microflora), acetylsalicylic acid, dipyridamole, non-steroidal anti-inflammatory drugs and other drugs that reduce platelet aggregation (remaining the main mechanism of hemostasis in patients with heparin therapy), indirect anticoagulants, drugs that block tubular secretion.

    Weaken - antihistamines, phenothiazines, cardiac glycosides, a nicotinic acid, ethacrynic acid, tetracyclines, ergot alkaloids, nicotine, nitroglycerine (intravenous administration), thyroxine, adrenocorticotropic hormone, alkaline amino acids and polypeptides, protamine.

    Do not mix in the same syringe with other medicines.

    Special instructions:

    Heparin can not be administered intramuscularly, because the formation of hematomas at the site of administration. A solution of heparin can acquire a yellow tint, which does not change its activity or tolerability.

    When prescribing heparin for medicinal purposes, its dose is selected depending on the value of APTTV.

    During the application of heparin, other drugs should not be given intramuscularly and organ biopsies should be performed.

    To dilute heparin use only 0.9% solution of sodium chloride.

    Although heparin does not penetrate into breast milk, the administration of it to nursing mothers in some cases caused a rapid (within 2-4 weeks) development of osteoporosis and spinal injury.

    Form release / dosage:Injection.
    Packaging:

    Solution for injections of 5 ml in bottles of neutral glass or 1, 2, 5 ml in neutral glass ampoules.

    5 bottles with instructions for use are placed in a pack of cardboard or a polystyrene container.

    5 vials are placed in a contour mesh package from a polyvinyl chloride film. 1 or 2 contour mesh packages with instructions for use are placed in a pack of cardboard.

    50 vials with an equal amount; instructions for use are placed in; a box of cardboard for delivery to hospitals.

    5 or 10 ampoules with instructions for use are placed in a cardboard box.

    5 ampoules are placed in a contour mesh box made of polyvinyl chloride film and foil of aluminum printed lacquered or without foil.

    1 or 2 contour mesh packages with instructions for use are placed in a pack of cardboard. In each box or a pack of ampoules, a scapegrator is inserted ampoule, In the case of using ampoules with a ring; fracture or with an incision and a break point the scarifier ampoule does not invest.

    Storage conditions:In a dry, protected from light place at a temperature of 8 to 25 ° C. Keep out of the reach of children.
    Shelf life:4 years.Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N000116 / 01
    Date of registration:01.10.2007 / 06.11.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.03.2017
    Illustrated instructions
      Instructions
      Up